Wednesday, July 8, 2026

biotech · Relapsed or Refractory B-cell Malignancies · Solid Tumor · RXRX

RECURSION PHARMACEUTICALS

RECURSION PHARMACEUTICALS is a biotech organization headquartered in Staten Island, USA. It trades on NYSE under ticker RXRX. Primary therapeutic focus areas include Relapsed or Refractory B-cell Malignancies, Solid Tumo

Staten Island, USA HQ
11 Employees
Public company Type
RXRX · NYSE Ticker
Company details
Status
Public
HQ
Staten Island, USA
Employees
11
Programs
9
Drugs
2
Patents
4
Clinical program

EXS73565

Phase 1 · small molecule · Relapsed or Refractory B-cell Malignancies

EXS73565 for Relapsed or Refractory B-cell Malignancies is a Phase 1 program (small_molecule) at RECURSION PHARMACEUTICALS, INC. with 1 ClinicalTrials.gov record(s).

Internal code EXS73565-001

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
RECURSION PHARMACEUTICALS, INC.
Phase
Phase 1
Modality
small_molecule
Indication
Relapsed or Refractory B-cell Malignancies
Status
active
Trials
1